Document is current
Any future updates will be listed below
-
Authors
Kolevzon, Alexander
Ventola, Pamela
Keary, Christopher J.
Heimer, Gali
Neul, Jeffrey L.
Adera, Mathews
Jaeger, Judith
-
Funding
Funding for this research was provided by:
Ovid Therapeutics, Inc.
- License Information
-
More Information
Article History
Received: 7 July 2020
Accepted: 1 December 2020
First Online: 4 January 2021
Ethics approval and consent to participate
: Participants (caregivers and expert clinicians) read and signed a Release and Confidentiality Agreement. Internal Review Board reviews were not applicable to these market research projects.
: Not applicable
: AK receives research support from AMO Pharma and has received compensation from Ovid Therapeutics, Inc. for consulting and serving on the scientific advisory board. PV has no conflicts of interest to declare. CK has received compensation from Ovid Therapeutics, Inc. for consulting, research funding and serving on a scientific advisory board. GH has received compensation from Ovid Therapeutics, Inc. for serving on a scientific advisory board and has no other conflicts to declare. JLN has received compensation from Ovid Therapeutics, Inc. for consulting and serving on a scientific advisory board. MA is an employee and shareholder of Ovid Therapeutics, Inc. JJ is owner of CognitionMetrics, LLC, which has received compensation on her behalf for consulting and serving on a scientific advisory board for Ovid Therapeutics, Inc.
